|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
April 16, 2012 : How Strong is Your Pradaxa Case?
|
|
If your doctor has prescribed the relatively new drug, Pradaxa, as an alternative to Warfarin, you may have been alarmed to hear of the potential issues with Pradaxa. Pradaxa was approved by the FDA in late 2010 after the manufacturer, Boehringer Ingelheim, presented the drug as a much better alternative to Warfarin.
|
|
Read More...
|
|
|
|
|
April 16, 2012 : How Strong is Your Pradaxa Case?
|
|
If your doctor has prescribed the relatively new drug, Pradaxa, as an alternative to Warfarin, you may have been alarmed to hear of the potential issues with Pradaxa. Pradaxa was approved by the FDA in late 2010 after the manufacturer, Boehringer Ingelheim, presented the drug as a much better alternative to Warfarin.
|
|
Read More...
|
|
|
|
|
April 01, 2012 : The Dangers of Pradaxa (Dabigatran) Part 3 of 3: Serious Vascular Risks
|
|
Pradaxa, the drug which less than a couple of years ago seemed like a dream come true for the hundreds of thousands of patients who were taking Warfarin or Coumadin has had its initial glow tarnished by the ever-increasing number of reports of serious side effects from use of the drug. Although Warfarin has been used as a stroke inhibitor and for those suffering from atrial fibrillation since the 1950’s, it comes with certain restrictions and its own set of side effects.
|
|
Read More...
|
|
|
|
|
April 01, 2012 : The Dangers of Pradaxa (Dabigatran) Part 3 of 3: Serious Vascular Risks
|
|
Pradaxa, the drug which less than a couple of years ago seemed like a dream come true for the hundreds of thousands of patients who were taking Warfarin or Coumadin has had its initial glow tarnished by the ever-increasing number of reports of serious side effects from use of the drug. Although Warfarin has been used as a stroke inhibitor and for those suffering from atrial fibrillation since the 1950’s, it comes with certain restrictions and its own set of side effects.
|
|
Read More...
|
|
|
|
|
|
|
|
|
|
|
|
|
March 30, 2012 : Pradaxa (Dabigatran) Lawsuits
|
|
March of 2012 saw the first lawsuits filed against Boehringer Ingelheim, the manufacturer of Pradaxa. This drug was the first of its type to be marketed in over half a century, and Boehringer had high hopes that Pradaxa would knock its only competitor, Warfarin, out of the running in short order.
|
|
Read More...
|
|
|
|
|
March 30, 2012 : Pradaxa (Dabigatran) Lawsuits
|
|
March of 2012 saw the first lawsuits filed against Boehringer Ingelheim, the manufacturer of Pradaxa. This drug was the first of its type to be marketed in over half a century, and Boehringer had high hopes that Pradaxa would knock its only competitor, Warfarin, out of the running in short order.
|
|
Read More...
|
|
|
|
|
|
|
|
|
|
|
|
|
March 28, 2012 : Pradaxa (Dabigatran) and the FDA Safety Review
|
|
Although only on the market for a relatively short period of time, Pradaxa, the blood-thinning drug manufactured by Boehringer Ingelheim—has already suffered under the weight of threatened recalls, lawsuits and warnings by the FDA. Pradaxa is the first FDA-approved drug of its type since the drug Warfarin was approved in 1954.
|
|
Read More...
|
|
|
|
|
March 28, 2012 : Pradaxa (Dabigatran) and the FDA Safety Review
|
|
Although only on the market for a relatively short period of time, Pradaxa, the blood-thinning drug manufactured by Boehringer Ingelheim—has already suffered under the weight of threatened recalls, lawsuits and warnings by the FDA. Pradaxa is the first FDA-approved drug of its type since the drug Warfarin was approved in 1954.
|
|
Read More...
|
|
|
|
|
March 03, 2012 : Actos Discussions Part 2: Dangers of the Drug
|
|
Links to higher heart disease rates have been associated with the use of Actos, and, in fact, Actos may cause as many heart problems as GlaxoSmithKline’s drug, Avandia. The American Heart Association reported that studies showed patients taking either diabetes drug were at least four times as likely to experience heart attacks, heart failure or even death.
|
|
Read More...
|
|
|
|
|
March 02, 2012 : Actos Discussions Part 1: Your Actos Case
|
|
Hundreds of thousands of patients who have taken the drug Actos over the past few years—believing the drug to be safe—have been very disillusioned to find that the drug can have some potentially very serious side effects. Actos is a drug which was developed for the treatment of Type 2 diabetes and works by helping the body restore its normal response to insulin, effectively lowering blood sugar.
|
|
Read More...
|
|
|
|
|
October 25, 2011 : How to Choose an Attorney for an Actos® Lawsuit
|
|
Actos is a widely-used medication for the treatment of Type 2 diabetes. Actos works by helping to regulate blood sugar levels, making your body more insulin-sensitive. Doctors frequently recommend taking Actos in conjunction with a sensible diet and regular exercise for those who have the type of diabetes which does not necessitate taking insulin.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® Adverse Effects
|
|
Many of us would be very surprised to find that a drug can be approved by the FDA yet still have serious—and undisclosed—side effects. The drug Actos, used in the treatment of Type 2 diabetes, is one such drug. Actos works by decreasing the body’s resistance to insulin as a way of controlling blood sugar levels. Actos is currently being used by millions of people across the globe, with sales jumping from around $2.9 billion in 2006 to over $4.3 billion in 2010.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Bladder Cancer
|
|
Recent studies have shown that patients taking the drug Actos for longer than one year may suffer significantly increased risks of developing bladder cancer. The FDA warnings are being issued on the heels of France and Germany banning the use of Actos, and New Zealand also beginning the process of removing Actos from patient use.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Cardiovascular Dangers
|
|
The drug Actos, marketed by Takeda Pharmaceutical Corporation, is used in the treatment of Type 2 diabetes. Actos largely replaced its predecessor, Avandia, after Avandia was found to have serious risks of heart attack and heart failure. At the time, it was believed that Actos offered much less risk of cardiovascular damage than Avandia. Actos is used to lessen blood glucose labels and improves how the body handles insulin.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Congestive Heart Failure
|
|
The drug Actos, also known as pioglitazone is marketed by Takeda Pharmaceuticals and Eli Lilly for the treatment of Type 2 diabetes. The drug was approved in 1999, and although the manufacturer touts it as a miracle drug which has reduced the number of diabetes cases by as much as 70%, the side effects may far outweigh the benefits. A study done in 2003 by the Mayo Clinic definitively linked Actos to swelling in the feet, lung fluid retention, shortness of breath and congestive heart failure.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Myocardial Infarction
|
|
After a Journal of American Medical Association publication of a meta-analysis suggested that long-term use of the diabetes drug Avandia was associated with an increased risk of myocardial infarction, the maker of Avandia, GlaxoSmithKline, declared there was little difference in the safety profile of their drug, Avandia and the “other” drug for Type 2 diabetes, Takeda Pharmaceutical’s Actos. Further studies however have not completely backed up that declaration.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® Damages and Typical Settlements
|
|
The Type 2 diabetes drug Actos is one of a class of drugs known as thiazolidinediones and has recently been linked to an increased risk of bladder cancer, liver disease and cardiovascular issues. The FDA felt that the link between heart failure and Actos was serious enough to require increased warnings on the drug packaging concerning congestive heart failure.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® European Recall and FDA Stance
|
|
A wave of recent studies which definitively link the prescription drug Actos—prescribed for Type 2 diabetes—to bladder cancer gives a fairly clear indication that Takeda Pharmaceuticals may soon be flooded with Actos lawsuits. August, 2011, saw the first Actos lawsuit filed by a 54-year old woman from Pennsylvania who had taken Actos for over a decade, then was diagnosed with bladder cancer.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® FDA Safety Review/Warning
|
|
United States Food and Drug Administration informed the public that using the drug Actos, commonly prescribed in the treatment of Type 2 diabetes, has been positively associated with an increased risk of bladder cancer. Actos is manufactured by a Japanese pharmaceutical company, Takeda Pharmaceuticals, and is typically sold either as a single-ingredient product or in combination with the drug metformin.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® Side Effects other than Heart Disease and Bladder Cancer
|
|
While many people are now aware of the association between the Type 2 diabetes drug, Actos, and both bladder cancer and heart disease, there are several other quite serious side effects also associated with the drug. For instance, there is strong evidence to suggest that Actos, like its sister-drug, Avandai, may cause osteoporosis and bone fractures among those taking it, most especially in female patients.
|
|
Read More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 25, 2011 : European Medicines Agency Scientific Studies on Pioglitazone
|
|
The European Medicines Agency released a scientific study on the benefits and risks of the drug pioglitazone, also known as Actos, in January of 2007. This drug is currently used as a single treatment for Type 2 diabetes or in a dual combination form with metformin or sulphonylurea. When used alone, pioglitazone is typically used as therapy for the overweight patient whose Type 2 diabetes is not being controlled through diet and exercise and for whom the drug metformin is inappropriate.
|
|
Read More...
|
|
|
|
|
September 24, 2011 : FDA Approves Cancer Warning for Diabetic Drug Actos
|
|
The blockbuster drug, Actos, which is prescribed to control Type 2 diabetes, has received new warning language on the label regarding a potential risk of bladder cancer for those taking the drug. Actos, also known as pioglitazone, is manufactured by Takeda Pharmaceuticals, a Japanese-based company, and is currently their best-selling drug, with sales of $3.4 billion last year alone.
|
|
Read More...
|
|
|
|
|
September 23, 2011 : Takeda Pharmaceuticals Received FDA Instructions for Diabetic Drug Actos
|
|
The drug Actos, also known as pioglitazone, has recently come under fire due to studies showing a slight increased risk of bladder cancer in those taking high doses of the drug or those who have taken Actos for longer than two years. Manufactured by Takeda Pharmaceuticals of Japan, the drug has shown huge gains in popularity in the past few years as it quickly replaced the drug Avandia which suffered under claims of increased risk of heart attack and death.
|
|
Read More...
|
|
|
|
|
|
|
|
|
September 05, 2011 : Depakote Birth Defects: Real Risks
|
|
Depakote is a prescription drug used to treat epileptic seizures, psychological disorders such as bipolar disorder, and migraine headaches. Depakote is marketed under several brand names and generic versions of the drug, including Depakote ER, Depakote Sprinkles, Depakene, and Valproate.
|
|
Read More...
|
|
|
|
|
September 05, 2011 : Depakote Birth Defects: Real Risks
|
|
Depakote is a prescription drug used to treat epileptic seizures, psychological disorders such as bipolar disorder, and migraine headaches. Depakote is marketed under several brand names and generic versions of the drug, including Depakote ER, Depakote Sprinkles, Depakene, and Valproate.
|
|
Read More...
|
|
|
|
|
|
|
|
|
|
|
|
|
March 02, 2012 : Actos Discussions Part 1: Your Actos Case
|
|
Hundreds of thousands of patients who have taken the drug Actos over the past few years—believing the drug to be safe—have been very disillusioned to find that the drug can have some potentially very serious side effects. Actos is a drug which was developed for the treatment of Type 2 diabetes and works by helping the body restore its normal response to insulin, effectively lowering blood sugar.
|
|
Read More...
|
|
|
|
|
March 03, 2012 : Actos Discussions Part 2: Dangers of the Drug
|
|
Links to higher heart disease rates have been associated with the use of Actos, and, in fact, Actos may cause as many heart problems as GlaxoSmithKline’s drug, Avandia. The American Heart Association reported that studies showed patients taking either diabetes drug were at least four times as likely to experience heart attacks, heart failure or even death.
|
|
Read More...
|
|
|
|
|
October 25, 2011 : How to Choose an Attorney for an Actos® Lawsuit
|
|
Actos is a widely-used medication for the treatment of Type 2 diabetes. Actos works by helping to regulate blood sugar levels, making your body more insulin-sensitive. Doctors frequently recommend taking Actos in conjunction with a sensible diet and regular exercise for those who have the type of diabetes which does not necessitate taking insulin.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® Adverse Effects
|
|
Many of us would be very surprised to find that a drug can be approved by the FDA yet still have serious—and undisclosed—side effects. The drug Actos, used in the treatment of Type 2 diabetes, is one such drug. Actos works by decreasing the body’s resistance to insulin as a way of controlling blood sugar levels. Actos is currently being used by millions of people across the globe, with sales jumping from around $2.9 billion in 2006 to over $4.3 billion in 2010.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Bladder Cancer
|
|
Recent studies have shown that patients taking the drug Actos for longer than one year may suffer significantly increased risks of developing bladder cancer. The FDA warnings are being issued on the heels of France and Germany banning the use of Actos, and New Zealand also beginning the process of removing Actos from patient use.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Cardiovascular Dangers
|
|
The drug Actos, marketed by Takeda Pharmaceutical Corporation, is used in the treatment of Type 2 diabetes. Actos largely replaced its predecessor, Avandia, after Avandia was found to have serious risks of heart attack and heart failure. At the time, it was believed that Actos offered much less risk of cardiovascular damage than Avandia. Actos is used to lessen blood glucose labels and improves how the body handles insulin.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Congestive Heart Failure
|
|
The drug Actos, also known as pioglitazone is marketed by Takeda Pharmaceuticals and Eli Lilly for the treatment of Type 2 diabetes. The drug was approved in 1999, and although the manufacturer touts it as a miracle drug which has reduced the number of diabetes cases by as much as 70%, the side effects may far outweigh the benefits. A study done in 2003 by the Mayo Clinic definitively linked Actos to swelling in the feet, lung fluid retention, shortness of breath and congestive heart failure.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® and Myocardial Infarction
|
|
After a Journal of American Medical Association publication of a meta-analysis suggested that long-term use of the diabetes drug Avandia was associated with an increased risk of myocardial infarction, the maker of Avandia, GlaxoSmithKline, declared there was little difference in the safety profile of their drug, Avandia and the “other” drug for Type 2 diabetes, Takeda Pharmaceutical’s Actos. Further studies however have not completely backed up that declaration.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® Damages and Typical Settlements
|
|
The Type 2 diabetes drug Actos is one of a class of drugs known as thiazolidinediones and has recently been linked to an increased risk of bladder cancer, liver disease and cardiovascular issues. The FDA felt that the link between heart failure and Actos was serious enough to require increased warnings on the drug packaging concerning congestive heart failure.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® European Recall and FDA Stance
|
|
A wave of recent studies which definitively link the prescription drug Actos—prescribed for Type 2 diabetes—to bladder cancer gives a fairly clear indication that Takeda Pharmaceuticals may soon be flooded with Actos lawsuits. August, 2011, saw the first Actos lawsuit filed by a 54-year old woman from Pennsylvania who had taken Actos for over a decade, then was diagnosed with bladder cancer.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® FDA Safety Review/Warning
|
|
United States Food and Drug Administration informed the public that using the drug Actos, commonly prescribed in the treatment of Type 2 diabetes, has been positively associated with an increased risk of bladder cancer. Actos is manufactured by a Japanese pharmaceutical company, Takeda Pharmaceuticals, and is typically sold either as a single-ingredient product or in combination with the drug metformin.
|
|
Read More...
|
|
|
|
|
October 21, 2011 : Actos® Side Effects other than Heart Disease and Bladder Cancer
|
|
While many people are now aware of the association between the Type 2 diabetes drug, Actos, and both bladder cancer and heart disease, there are several other quite serious side effects also associated with the drug. For instance, there is strong evidence to suggest that Actos, like its sister-drug, Avandai, may cause osteoporosis and bone fractures among those taking it, most especially in female patients.
|
|
Read More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 25, 2011 : European Medicines Agency Scientific Studies on Pioglitazone
|
|
The European Medicines Agency released a scientific study on the benefits and risks of the drug pioglitazone, also known as Actos, in January of 2007. This drug is currently used as a single treatment for Type 2 diabetes or in a dual combination form with metformin or sulphonylurea. When used alone, pioglitazone is typically used as therapy for the overweight patient whose Type 2 diabetes is not being controlled through diet and exercise and for whom the drug metformin is inappropriate.
|
|
Read More...
|
|
|
|
|
September 24, 2011 : FDA Approves Cancer Warning for Diabetic Drug Actos
|
|
The blockbuster drug, Actos, which is prescribed to control Type 2 diabetes, has received new warning language on the label regarding a potential risk of bladder cancer for those taking the drug. Actos, also known as pioglitazone, is manufactured by Takeda Pharmaceuticals, a Japanese-based company, and is currently their best-selling drug, with sales of $3.4 billion last year alone.
|
|
Read More...
|
|
|
|
|
September 23, 2011 : Takeda Pharmaceuticals Received FDA Instructions for Diabetic Drug Actos
|
|
The drug Actos, also known as pioglitazone, has recently come under fire due to studies showing a slight increased risk of bladder cancer in those taking high doses of the drug or those who have taken Actos for longer than two years. Manufactured by Takeda Pharmaceuticals of Japan, the drug has shown huge gains in popularity in the past few years as it quickly replaced the drug Avandia which suffered under claims of increased risk of heart attack and death.
|
|
Read More...
|
|
|
|
|
|
|
|